Article Text

Download PDFPDF
11 Meta-analysis of prognostic value of transforming growth factor-beta (tgf-β) in patients
  1. F Wang
  1. Zhoukou Normal University, Henan, China


Objectives Transforming growth factor-beta (TGF-β) is associated with a higher incidence of distant metastasis and decreased survival. Whether TGF-β can be used as a prognostic indicator of colorectal cancer (CRC) remains controversial.

Methods The Medline, EMBASE and Cochrane databases were searched from their inception to March 2016. The studies that focused on TGF-β as a prognostic factor in patients with CRC were included in this analysis. Overall survival (OS) and disease-free survival (DFS) were analysed separately. A meta-analysis was performed, and hazard ratios (HR) with 95% confidence intervals (CI) were calculated.

Results Twelve studies were included in the analysis, of which 8 were used for OS and 7 for DFS. In all, 1622 patients with CRC undergoing surgery were included. Combined HRs suggested that high expression of TGF-β had a favourable impact on OS (HR=1.68, 95% CI 1.10 to 2.59) and DFS (HR=1.11, 95% CI 1.03 to 1.19) in CRC patients. For OS, the combined HRs of Asian studies and Western studies were 1.50 (95% CI 0.61 to 3.68) and 1.80 (95% CI 1.33 to 2.45), respectively. For DFS, the combined HRs of Asian studies and Western studies were 1.42 (95% CI 0.61 to 3.31) and 1.11 (95% CI 1.03 to 1.20), respectively.

Conclusions This meta-analysis demonstrates that TGF-β can be used as a prognostic biomarker for CRC patients undergoing surgery, especially for CRC patients from Western countries.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.